NGNE (Neurogene, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by NGNE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | Christine Mikail Cvijic | President and CFO | Sell | — | — |
| 2026-07-02 | Christine Mikail Cvijic | President and CFO | Sell | — | — |
| 2026-06-16 | Keith Woods | Director | A | — | — |
| 2026-06-16 | Keith Woods | Director | A | — | — |
| 2026-06-16 | Keith Woods | Director | A | — | — |
| 2026-05-08 | Christine Mikail Cvijic | President and CFO | Sell | — | — |
| 2026-05-07 | Christina Shafer | Chief Commercial Officer | A | — | — |
| 2026-03-30 | Julie Jordan | Chief Medical Officer | Sell | — | — |
| 2026-03-30 | Rachel McMinn | Chief Executive Officer | Sell | — | — |
| 2026-03-30 | Christine Mikail Cvijic | President and CFO | Sell | — | — |
| 2026-03-17 | Stuart Cobb | Chief Scientific Officer | Sell | — | — |
| 2026-03-17 | Christine Mikail Cvijic | President and CFO | Sell | — | — |
| 2026-03-03 | Christine Mikail Cvijic | President and CFO | Sell | — | — |
| 2026-02-24 | Stuart Cobb | Chief Scientific Officer | A | — | — |
| 2026-02-24 | Cory S. Freedland | Director | A | — | — |
| 2026-02-24 | ROHAN PALEKAR | Director | A | — | — |
| 2026-02-24 | Sarah B. Noonberg | Director | A | — | — |
| 2026-02-24 | Keith Woods | Director | A | — | — |
| 2026-02-24 | ROBERT BAFFI | Director | A | — | — |
| 2026-02-24 | Julie Jordan | Chief Medical Officer | A | — | — |
| 2026-02-24 | Rachel McMinn | Chief Executive Officer | A | — | — |
| 2026-02-24 | Christine Mikail Cvijic | President and CFO | A | — | — |
| 2025-06-13 | Robert Keith Woods | Director | A | — | — |
| 2025-06-13 | Sarah B. Noonberg | Director | A | — | — |
| 2025-06-13 | ROBERT BAFFI | Director | A | — | — |
| 2025-06-13 | Cory S. Freedland | Director | A | — | — |
| 2025-06-13 | ROHAN PALEKAR | Director | A | — | — |
| 2025-05-15 | Stuart Cobb | Chief Scientific Officer | Sell | — | — |
| 2025-03-28 | Stuart Cobb | Chief Scientific Officer | A | — | — |
| 2025-03-28 | Julie Jordan | Chief Medical Officer | A | — | — |
| 2025-03-28 | Christine Mikail Cvijic | President and CFO | A | — | — |
| 2025-03-28 | Rachel McMinn | Chief Executive Officer | A | — | — |
| 2025-03-17 | Christine Mikail Cvijic | President and CFO | Sell | — | — |
| 2024-11-27 | Samsara BioCapital, L.P. | 10%+ Owner | Buy | — | — |
| 2024-11-25 | Christine Mikail Cvijic | President and CFO | Buy | — | — |
| 2024-11-25 | Rachel McMinn | Chief Executive Officer | Buy | — | — |
| 2024-06-17 | Sarah B. Noonberg | Director | A | — | — |
| 2024-06-17 | Cory S. Freedland | Director | A | — | — |
| 2024-06-17 | ROHAN PALEKAR | Director | A | — | — |
| 2024-06-17 | Robert Keith Woods | Director | A | — | — |
| 2024-06-17 | ROBERT BAFFI | Director | A | — | — |
| 2024-03-14 | Stuart Cobb | Chief Scientific Officer | A | — | — |
| 2024-03-14 | Rachel McMinn | Chief Executive Officer | A | — | — |
| 2024-03-14 | Christine Mikail Cvijic | President and CFO | A | — | — |
| 2024-01-18 | ROBERT BAFFI | Director | A | — | — |
| 2024-01-18 | Julie Jordan | Chief Medical Officer | A | — | — |
| 2024-01-18 | Robert Keith Woods | Director | A | — | — |
| 2024-01-18 | Cory S. Freedland | Director | A | — | — |
| 2024-01-18 | Sarah B. Noonberg | Director | A | — | — |
| 2024-01-18 | ROHAN PALEKAR | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,717,127 | — |
| — | Chief Executive Officer | 1,344,307 | — |
| — | President and CFO | 88,240 | — |
| — | Director | 39,081 | — |
| — | Chief Scientific Officer | 33,303 | — |
| — | Chief Medical Officer | 12,472 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NGNE quote page; the site-wide leaderboard is on the insider transactions hub.